Meningococcal vax positive
The efficacy of meningococcal group B vaccine, 4CMenB, has been demonstrated in findings from the B Part of It study – the largest meningococcal B herd immunity study – with almost 35,000 school students, aged 15 to 18 years.
The B Part of It study was carried out in South Australia between 2017 and 2018 and authors have reported there has been no reported cases of meningococcal disease amongst the students since the study began. In the two years prior to the study, there was 12 reported cases.
Although the study has demonstrated the effectiveness of the vaccination, there was also no reduction in the percentage of students who were carrying the bacteria, including the B strain, which highlights the efficacy of 4CMenB only for the vaccinated as vaccine’s ability to reduce B strain transmission is unlikely.